Description
Trimbow 87/5/9 is a prescription-only pressurised metered-dose inhaler containing three maintenance medicines in every delivered actuation: 87 micrograms of beclometasone dipropionate, 5 micrograms of formoterol fumarate dihydrate and 9 micrograms of glycopyrronium. The Turkish product information authorises this strength for maintenance treatment of adults with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated with appropriate dual inhaled therapy.

Important: Trimbow 87/5/9 is not a rescue inhaler for sudden breathlessness or an acute COPD attack. It must be used regularly exactly as prescribed, while any separate reliever medicine recommended by the treating clinician remains available for acute symptoms.
Trimbow 87/5/9 quick facts
| Medicine | Trimbow 87/5/9 micrograms pressurised inhalation solution |
|---|---|
| Delivered dose | Beclometasone dipropionate 87 mcg + formoterol fumarate dihydrate 5 mcg + glycopyrronium 9 mcg per actuation |
| Therapy type | ICS/LABA/LAMA fixed-dose triple maintenance therapy |
| Turkish indication | Maintenance treatment of adults with moderate-to-severe COPD not adequately treated with ICS/LABA or LABA/LAMA therapy |
| Recommended adult dose | Two inhalations twice daily |
| Maximum dose | Two inhalations twice daily |
| Pack | Pressurised inhaler with 120 actuations |
| Supply | Prescription only |
What Trimbow 87/5/9 is used for
Trimbow 87/5/9 is used as ongoing maintenance treatment, not as an occasional symptom medicine. COPD can involve persistent airflow limitation, airway inflammation, narrowing of the bronchial muscles and repeated exacerbations. Some adults continue to have symptoms or flare-ups even when they already use two long-acting treatment components. A clinician may then consider a fixed triple combination when it is appropriate for that patient’s diagnosis, exacerbation history, lung function and current inhaler regimen.
The Turkish summary of product characteristics for this specific pack describes COPD maintenance use. Regulations and approved indications can differ between countries, so the prescription label and the leaflet supplied with the Turkish medicine should guide use. Never transfer an indication or dose from another country’s pack without medical confirmation.
How the three active ingredients work
The three components of Trimbow 87/5/9 have complementary roles. Beclometasone dipropionate is an inhaled corticosteroid (ICS) that reduces inflammatory activity in the airways. Formoterol is a long-acting beta2-agonist (LABA) that relaxes bronchial smooth muscle. Glycopyrronium is a long-acting muscarinic antagonist (LAMA) that blocks muscarinic signals involved in airway constriction. Combining them in one inhaler provides anti-inflammatory treatment plus two different long-acting bronchodilator mechanisms.
This does not mean that more medicine is always better. Triple therapy should follow a clinical assessment. The prescriber reviews the patient’s previous medicines, exacerbations, symptoms, inhaler technique and risks such as pneumonia, cardiac disease, glaucoma or urinary retention before deciding whether the combination is suitable.
Why correct inhaler technique matters
A pressurised metered-dose inhaler delivers medicine only when activation and inhalation are coordinated. Poor timing, breathing in too quickly, an incomplete breath or failing to hold the breath may reduce the dose reaching the lungs. The official product information says a doctor or another healthcare professional should show the patient how to use the inhaler correctly and should check technique regularly.
- Stand or sit upright and remove the mouthpiece cover.
- Check that the mouthpiece is clean and free from dust or foreign objects.
- Hold the inhaler upright and breathe out slowly, away from the device.
- Place the mouthpiece between the teeth and close the lips around it without biting.
- Begin a slow, deep inhalation and press the canister once while continuing to breathe in steadily.
- Hold the breath for as long as is comfortable, then breathe out slowly away from the inhaler.
- Wait before the second actuation and repeat the prescribed steps.
- Rinse the mouth or gargle with water after the dose and spit it out.
These are general technique reminders, not a substitute for the illustrated leaflet. If hand-breath coordination is difficult, ask the prescriber or pharmacist whether a compatible spacer is appropriate and how it should be used.
Recommended Trimbow 87/5/9 dose in Turkey
For adults aged 18 years and over, the Turkish product information recommends two inhalations twice daily. The same amount is stated as the maximum dose. Use the inhaler at consistent times and follow the individual prescription. Do not add extra actuations because symptoms feel worse. A sudden increase in breathlessness, wheeze or reliever use may indicate deterioration that needs medical review.
If a dose is missed, follow the patient leaflet or ask a pharmacist. Do not double the next dose unless a healthcare professional specifically instructs this. Patients should not stop Trimbow 87/5/9 abruptly merely because they feel better, because COPD maintenance control depends on regular treatment.
Trimbow 87/5/9 is not for acute attacks
Trimbow 87/5/9 should not be started to treat an acute COPD exacerbation and should not be used as the rescue medicine for sudden bronchospasm. A patient who develops acute or rapidly worsening breathlessness should use the emergency plan supplied by the treating clinician and seek urgent medical help when symptoms are severe, unusual or not responding to the prescribed reliever.
Immediate assessment is especially important for severe difficulty breathing, blue or grey lips, confusion, chest pain, fainting or an inability to speak in full sentences. Do not wait for the next routine appointment in these situations.
Who should not use it
Trimbow 87/5/9 must not be used by anyone with hypersensitivity to beclometasone dipropionate, formoterol fumarate dihydrate, glycopyrronium bromide or any excipient in the formulation. The Turkish pack also contains norflurane propellant, ethanol and hydrochloric acid as excipients. The full ingredient list should be checked if there is a history of medicine allergy.
This product is not intended for children or adolescents under 18 years in the Turkish COPD indication. Pregnancy, plans for pregnancy and breastfeeding must be discussed with the prescriber so that benefits and potential risks can be assessed individually.
Conditions that need extra caution
Tell the clinician before using Trimbow 87/5/9 if there is a history of heart rhythm problems, recent myocardial infarction, heart failure, severe cardiovascular disease, high blood pressure, an overactive thyroid, diabetes, low blood potassium, severe liver or kidney impairment, narrow-angle glaucoma, prostate problems or urinary retention. Also mention active or previous pulmonary tuberculosis and untreated infections.
Inhaled corticosteroids may be associated with pneumonia in people with COPD. New fever, chills, increased sputum, a change in sputum colour or a clear deterioration in breathing should be reported promptly because pneumonia and a COPD exacerbation can have similar symptoms.
Common and important side effects
Possible effects reflect the three drug classes and may include oral candidiasis (thrush), hoarseness or voice change, throat irritation, dry mouth, headache, muscle spasms, tremor, palpitations or cough. Rinsing the mouth after each dose and maintaining good inhaler hygiene can reduce some local steroid-related effects.
Seek urgent care for swelling of the face, lips, tongue or throat; hives with breathing difficulty; or severe dizziness, because these may indicate a serious allergic reaction. If breathing or wheezing becomes suddenly worse immediately after inhalation, stop using the device and obtain urgent medical advice because paradoxical bronchospasm can occur with inhaled medicines.
Eye pain, blurred vision, halos around lights, marked difficulty passing urine, sustained rapid heartbeat or severe muscle weakness also require prompt medical attention. This list is not complete; the package leaflet contains the full frequency-based side-effect information.
Interactions to discuss with the prescriber
Provide a complete list of prescription medicines, over-the-counter products and herbal preparations. Important groups include other beta-adrenergic bronchodilators, other anticholinergic medicines, beta-blockers, medicines that can prolong the QT interval, monoamine oxidase inhibitors, tricyclic antidepressants, some antihistamines, non-potassium-sparing diuretics, systemic corticosteroids and xanthine derivatives.
Strong CYP3A inhibitors may increase systemic exposure to beclometasone and can raise the risk of corticosteroid adverse effects. The treating clinician should know about medicines such as ritonavir or cobicistat-containing products and relevant antifungals. Do not stop an interacting medicine independently; the clinician decides whether monitoring, substitution or dose changes are needed.
Monitoring during treatment
Follow-up may include symptom review, COPD exacerbation frequency, reliever use, oxygen status and lung-function testing such as spirometry. Clinicians also recheck technique and adherence because an apparent lack of response may be caused by device errors or missed doses rather than treatment failure.
Depending on individual risk, monitoring may include blood potassium, blood glucose, heart rhythm, eye symptoms, urinary symptoms, bone health or signs of systemic corticosteroid exposure. The minimum effective treatment should always be selected by the prescriber according to current clinical control.
Cleaning and device care
Keep the mouthpiece clean and dry and replace its cap after use. Do not pierce, break or burn the pressurised canister, even when it appears empty. Follow the Turkish leaflet for the exact cleaning method because immersing parts that should remain dry can damage the device. Check the dose counter so a replacement can be arranged before the inhaler is exhausted.
Keep Trimbow 87/5/9 out of the sight and reach of children. Protect it from excessive heat and direct sunlight and follow the storage instructions on the Turkish carton and leaflet. Do not use it after the expiry date or if the device is damaged.
How to recognise the Turkish pack
The Turkish carton identifies the product as “TRİMBOW 87 mcg / 5 mcg / 9 mcg aerosol inhalasyonu, çözelti” and carries Chiesi branding. It states 120 doses and lists the three active ingredients. Check that the strength, dosage form, expiry details and batch information match the prescription. Do not rely on colour alone because packaging can be updated.
Purchase prescription medicines through authorised supply channels. If the carton seal, printing, device or leaflet appears unusual, do not use the inhaler until a pharmacist has checked it.
Trimbow 87/5/9 practical checklist
- Confirm the exact strength and Turkish label before first use.
- Use two inhalations twice daily only as prescribed.
- Ask for a live demonstration of inhaler technique.
- Rinse the mouth and spit out the water after each scheduled dose.
- Keep the separate rescue inhaler available if it has been prescribed.
- Watch the dose counter and arrange the next supply in advance.
- Report worsening breathing, infection symptoms or new adverse effects.
- Never share a prescription inhaler with another person.
Frequently asked questions
Can Trimbow 87/5/9 replace my rescue inhaler?
No. It is scheduled maintenance therapy and is not intended to treat sudden acute attacks. Follow the clinician’s rescue plan.
Can I take extra puffs when I feel breathless?
Do not exceed the prescribed maximum. Worsening symptoms or increased reliever use should prompt clinical assessment.
Why should I rinse my mouth?
Rinsing and spitting after the dose helps reduce local corticosteroid effects such as oral thrush and hoarseness.
Can I stop when my breathing improves?
Do not stop or reduce Trimbow 87/5/9 without the prescriber’s advice. COPD maintenance therapy is intended for regular use.
Is this strength suitable for asthma?
Approved indications vary by country. This page follows the Turkish product information for the 87/5/9 pack, which describes COPD maintenance use. Follow the diagnosis and prescription issued by the treating clinician.
Official product information
For the Turkish indication, dosing and administration details, consult the official Chiesi Turkey Summary of Product Characteristics and the supplied patient leaflet. The European Medicines Agency Trimbow overview provides additional regulatory context. You can also browse our respiratory support products.
Summary
Trimbow 87/5/9 brings an inhaled corticosteroid, a LABA and a LAMA together in one pressurised inhaler for carefully selected adults with COPD. Its benefits depend on the right indication, regular twice-daily use, correct inhaler technique and ongoing medical review. It is a prescription maintenance medicine, not an emergency reliever.
Medical disclaimer: This educational product information does not replace the prescription, the Turkish package leaflet or advice from a physician or pharmacist. Do not start, stop or change any medicine without professional guidance.







Reviews
There are no reviews yet.